GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes
Completed
GW Research Ltd
Phase 2
This 15-19 week study is being conducted by GW Pharma Ltd as a pilot study in order to
determine the efficacy and safety of two cannabinoids: GWP42004 and GWP42003 alone, or in
combination in patients with Type 2 diabetes. This is the first study to determine whether
the study medications have a positive benefit for subjects on their cholesterol levels, body
weight, liver fat content and other metabolic parameters compared with a placebo medication.
A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes
Completed
GW Research Ltd
Phase 2
A study to compare the change in glycaemic control in participants with Type 2 diabetes when
treated with GWP42004 or placebo as add-on therapy to metformin over a period of 12 weeks.
The safety and tolerability of GWP42004 compared with placebo will also be assessed.
Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series
Recruiting
Gregory L Smith, MD, MPH
Early Phase 1
This is a case series of adult, male and female subjects with androgenetic alopecia (male
pattern baldness). A topical hemp oil that is rich in varins (THCV and CBDV) and cannabidiol
(CBD) is being used daily for six months to stimulate hair regrowth using Endocannabinoid
System (ECS) receptors that are found on hair follicles.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
